ClinicalTrials.gg
CompletedNCT00465088SUPREMEUpdated Jun 13, 2011Results posted

An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)

A Phase 3 interventional study of Niacin ER/Simvastatin Tablets and atorvastatin in Hyperlipidemia and Mixed Dyslipidemia, sponsored by Abbott. Completed at 46 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2011-06-13.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
199
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing simvastatin in Hyperlipidemias — 1 open to participants now, 1 under way, none of them phase 3. Simvastatin · Hyperlipidemias.

Enrollment
9th of 13
199 · median 516
Started
2007
the only one that year
Phase 3
9 of 14
none open now
Registered
9th of 14
by date
Lead sponsor
1 of 14
Abbott

Among the 14 studies testing simvastatin in Hyperlipidemias, this one is the 9th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2007, is one of 9 in phase 3, and was the 9th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

1 of the 14 studies testing simvastatin in Hyperlipidemias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About simvastatin

Simvastatin: first FDA approval 1991 (ZOCOR), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing simvastatin in Hyperlipidemias, or all of them as a file.
02

Study summary

To demonstrate that niacin ER and simvastatin (NS) tablets, when compared to atorvastatin (Lipitor®; Pfizer, Inc.), has superior high-density lipoprotein cholesterol (HDL-C) elevating effects at Week 12 in subjects with type II hyperlipidemia or mixed dyslipidemia who are currently off lipid-modifying therapy. This was a prospective, randomized, open-label, blinded endpoint (PROBE) study.

03

Conditions studied

  • Hyperlipidemia
  • Mixed Dyslipidemia

Browse trials for

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must meet all of the following laboratory criteria:

    • HDL-C \<40 mg/dL for men and \<50 mg/dL for women.
    • LDL-C ≥130 mg/dL but \<250 mg/dL.
    • TG \<350 mg/dL.
    • Creatine phosphokinase (CPK) \< 3 x (ULN).
    • (ALT); serum glutamic pyruvic transaminase [SGPT] and aspartate aminotransferase (AST); serum glutamic oxaloacetic transaminase [SGOT] \< 1.3 x ULN.
  • Subjects must also be reasonably compliant with the Therapeutic Lifestyle Changes (TLC) diet during the 4 to 5 week Screening Period prior to randomization (and be willing to comply for the duration of the study).

Exclusion criteria

Exclusion Criteria:

  • Subjects who have a history of any important medical conditions or abnormalities (as specified in the protocol) that would preclude study inclusion
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
199 participants (actual)

Study arms

  • Experimental
    1

    Drug: Niacin ER/Simvastatin Tablets

  • Experimental
    2

    Drug: atorvastatin

Interventions

  • DrugNiacin ER/Simvastatin Tablets

    Drug pages: Niacin · Simvastatin

    Up to 2000 mg/40 mg at bedtime

    Also known as: ABT-919/483, Niacin ER/Simvastatin, Simcor

  • 40 mg at bedtime

06

What researchers measure

Primary outcomes

  1. Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 12

    (Week 12 HDL-C minus baseline HDL-C) x 100/baseline HDL-C

    Time frame: From baseline to Week 12

Secondary outcomes

  1. Percent Change in HDL-C From Baseline to Week 8

    (Week 8 HDL-C minus baseline HDL-C) x 100/baseline HDL-C

    Time frame: From baseline to Week 8

  2. Percent Change in Non-HDL-C From Baseline to Week 8

    (Week 8 non-HDL-C minus baseline non-HDL-C) x 100/baseline non-HDL-C

    Time frame: From baseline to Week 8

  3. Percent Change in Non-HDL-C From Baseline to Week 12

    (Week 12 non-HDL-C minus baseline non-HDL-C) x 100/baseline non-HDL-C

    Time frame: From baseline to Week 12

  4. Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12

    (Week 12 LDL-C minus baseline LDL-C) x 100/baseline LDL-C

    Time frame: From baseline to Week 12

  5. Percent Change in Triglycerides From Baseline to Week 12

    (Week 12 triglycerides minus baseline triglycerides) x 100/baseline triglycerides

    Time frame: From baseline to Week 12

  6. Percent Change in LDL-C:HDL-C Ratio

    (Week 12 LDL-C:HDL-C ratio minus baseline LDL-C:HDL-C ratio) x 100/baseline LDL-C:HDL-C ratio

    Time frame: From baseline to Week 12

  7. Percent Change in Total Cholesterol From Baseline to Week 12

    (Week 12 total cholesterol minus baseline total cholesterol) x 100/baseline total cholesterol

    Time frame: From baseline to Week 12

  8. Percent Change in Total Cholesterol:HDL-C Ratio

    (Week 12 total cholesterol:HDL-C ratio minus baseline total cholesterol:HDL-C ratio) x 100/baseline total cholesterol:HDL-C ratio

    Time frame: From baseline to Week 12

  9. Percent Change in Lipoprotein A From Baseline to Week 12

    (Week 12 lipoprotein A minus baseline lipoprotein A) x 100/baseline lipoprotein A

    Time frame: From baseline to Week 12

  10. Percentage of Subjects Meeting With HDL-C >/= 40 mg/dL at Week 12

    Time frame: 12 weeks

  11. Percentage of Subjects Meeting National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III Goal for LDL-C at Week 12

    For high-risk patients (coronary heart disease or equivalent), LDL-C \< 100 mg/dL and non-HDL-C \< 130 mg/dL; for moderate risk patients (having 2 risk factors), LDL-C \< 130 mg/dL and non-HDL-C \< 160 mg/dL; for low-risk patients (having 0 or 1 risk factor): LDL-C \< 160 mg/dL and non-HDL-C \< 190 mg/dL.

    Time frame: 12 weeks

  12. Percentage of Subjects With Triglycerides < 150 mg/dL at Week 12

    Time frame: 12 weeks

  13. Percentage of Subjects With HDL-C >/= 40 mg/dL, LDL-C Meeting NCEP ATP III Goal, and Triglycerides < 150 mg/dL at Week 12

    NCEP ATP III goals for LDL-C are as follows: For high-risk patients, LDL-C \< 100 mg/dL; for moderate risk patients, LDL-C \< 130 mg/dL; for low-risk patients: LDL-C \< 160 mg/dL. High-risk means coronary heart disease or risk equivalents; moderate risk means having at least 2 risk factors; low-risk means having no or 1 risk factor.

    Time frame: 12 weeks

07

Results

Posted May 13, 2009

Participant flow

Participant flow — Overall Study
MilestoneNiacin Extended-release Plus SimvastatinAtorvastatin
Started11479
Completed8270
Not completed329

Outcome measures

PrimaryPercent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 12

(Week 12 HDL-C minus baseline HDL-C) x 100/baseline HDL-C

Time frame:
From baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 12
percent changeNiacin Extended-release Plus SimvastatinAtorvastatin
Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 1230.1 (25.6 to 34.6)9.4 (4.3 to 14.4)
Statistical analysis
  • Niacin Extended-release Plus Simvastatin vs Atorvastatin · Mixed Models Analysis · p = <0.001 (alpha = 0.05)
SecondaryPercent Change in HDL-C From Baseline to Week 8

(Week 8 HDL-C minus baseline HDL-C) x 100/baseline HDL-C

Time frame:
From baseline to Week 8
Reported as:
Least squares mean · percent change
Percent Change in HDL-C From Baseline to Week 8
percent changeNiacin Extended-release Plus SimvastatinAtorvastatin
Percent Change in HDL-C From Baseline to Week 826.7 (23.1 to 30.2)1.4 (-2.7 to 5.4)
SecondaryPercent Change in Non-HDL-C From Baseline to Week 8

(Week 8 non-HDL-C minus baseline non-HDL-C) x 100/baseline non-HDL-C

Time frame:
From baseline to Week 8
Reported as:
Least squares mean · percent change
Percent Change in Non-HDL-C From Baseline to Week 8
percent changeNiacin Extended-release Plus SimvastatinAtorvastatin
Percent Change in Non-HDL-C From Baseline to Week 8-45.0 (-48.9 to -41.0)-44.3 (-48.8 to -39.8)
SecondaryPercent Change in Non-HDL-C From Baseline to Week 12

(Week 12 non-HDL-C minus baseline non-HDL-C) x 100/baseline non-HDL-C

Time frame:
From baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change in Non-HDL-C From Baseline to Week 12
percent changeNiacin Extended-release Plus SimvastatinAtorvastatin
Percent Change in Non-HDL-C From Baseline to Week 12-43.4 (-47.7 to -39.0)-43.3 (-48.2 to -38.5)
SecondaryPercent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12

(Week 12 LDL-C minus baseline LDL-C) x 100/baseline LDL-C

Time frame:
From baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12
percent changeNiacin Extended-release Plus SimvastatinAtorvastatin
Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12-43.8 (-48.3 to -39.2)-46.0 (-51.0 to -40.9)
SecondaryPercent Change in Triglycerides From Baseline to Week 12

(Week 12 triglycerides minus baseline triglycerides) x 100/baseline triglycerides

Time frame:
From baseline to Week 12
Reported as:
Median · percent change
Percent Change in Triglycerides From Baseline to Week 12
percent changeNiacin Extended-release Plus SimvastatinAtorvastatin
Percent Change in Triglycerides From Baseline to Week 12-44.0 (-62.8 to -20.9)-37.0 (-47.8 to -18.8)
SecondaryPercent Change in LDL-C:HDL-C Ratio

(Week 12 LDL-C:HDL-C ratio minus baseline LDL-C:HDL-C ratio) x 100/baseline LDL-C:HDL-C ratio

Time frame:
From baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change in LDL-C:HDL-C Ratio
percent changeNiacin Extended-release Plus SimvastatinAtorvastatin
Percent Change in LDL-C:HDL-C Ratio-54.5 (-59.1 to -49.8)-50.5 (-55.7 to -45.3)
SecondaryPercent Change in Total Cholesterol From Baseline to Week 12

(Week 12 total cholesterol minus baseline total cholesterol) x 100/baseline total cholesterol

Time frame:
From baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change in Total Cholesterol From Baseline to Week 12
percent changeNiacin Extended-release Plus SimvastatinAtorvastatin
Percent Change in Total Cholesterol From Baseline to Week 12-31.3 (-34.8 to -27.7)-35.1 (-39.1 to -31.1)
SecondaryPercent Change in Total Cholesterol:HDL-C Ratio

(Week 12 total cholesterol:HDL-C ratio minus baseline total cholesterol:HDL-C ratio) x 100/baseline total cholesterol:HDL-C ratio

Time frame:
From baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change in Total Cholesterol:HDL-C Ratio
percent changeNiacin Extended-release Plus SimvastatinAtorvastatin
Percent Change in Total Cholesterol:HDL-C Ratio-45.2 (-49.0 to -41.3)-40.3 (-44.7 to -36.0)
SecondaryPercent Change in Lipoprotein A From Baseline to Week 12

(Week 12 lipoprotein A minus baseline lipoprotein A) x 100/baseline lipoprotein A

Time frame:
From baseline to Week 12
Reported as:
Median · percent change
Percent Change in Lipoprotein A From Baseline to Week 12
percent changeNiacin Extended-release Plus SimvastatinAtorvastatin
Percent Change in Lipoprotein A From Baseline to Week 12-15.8 (-36.8 to 8.8)16.0 (-7.1 to 30.8)
SecondaryPercentage of Subjects Meeting With HDL-C >/= 40 mg/dL at Week 12
Time frame:
12 weeks
Reported as:
Number · Percentage of subjects
Percentage of Subjects Meeting With HDL-C >/= 40 mg/dL at Week 12
Percentage of subjectsNiacin Extended-release Plus SimvastatinAtorvastatin
Percentage of Subjects Meeting With HDL-C >/= 40 mg/dL at Week 127828
SecondaryPercentage of Subjects Meeting National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III Goal for LDL-C at Week 12

For high-risk patients (coronary heart disease or equivalent), LDL-C \< 100 mg/dL and non-HDL-C \< 130 mg/dL; for moderate risk patients (having 2 risk factors), LDL-C \< 130 mg/dL and non-HDL-C \< 160 mg/dL; for low-risk patients (having 0 or 1 risk factor): LDL-C \< 160 mg/dL and non-HDL-C \< 190 mg/dL.

Time frame:
12 weeks
Reported as:
Number · Percentage of subjects
Percentage of Subjects Meeting National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III Goal for LDL-C at Week 12
Percentage of subjectsNiacin Extended-release Plus SimvastatinAtorvastatin
Percentage of Subjects Meeting National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III Goal for LDL-C at Week 127884
SecondaryPercentage of Subjects With Triglycerides < 150 mg/dL at Week 12
Time frame:
12 weeks
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Triglycerides < 150 mg/dL at Week 12
Percentage of subjectsNiacin Extended-release Plus SimvastatinAtorvastatin
Percentage of Subjects With Triglycerides < 150 mg/dL at Week 127970
SecondaryPercentage of Subjects With HDL-C >/= 40 mg/dL, LDL-C Meeting NCEP ATP III Goal, and Triglycerides < 150 mg/dL at Week 12

NCEP ATP III goals for LDL-C are as follows: For high-risk patients, LDL-C \< 100 mg/dL; for moderate risk patients, LDL-C \< 130 mg/dL; for low-risk patients: LDL-C \< 160 mg/dL. High-risk means coronary heart disease or risk equivalents; moderate risk means having at least 2 risk factors; low-risk means having no or 1 risk factor.

Time frame:
12 weeks
Reported as:
Number · Percentage of subjects
Percentage of Subjects With HDL-C >/= 40 mg/dL, LDL-C Meeting NCEP ATP III Goal, and Triglycerides < 150 mg/dL at Week 12
Percentage of subjectsNiacin Extended-release Plus SimvastatinAtorvastatin
Percentage of Subjects With HDL-C >/= 40 mg/dL, LDL-C Meeting NCEP ATP III Goal, and Triglycerides < 150 mg/dL at Week 126534

Adverse events

Non-serious events are listed at a 2.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Niacin Extended-release Plus Simvastatin———
Atorvastatin———
Most frequent serious events
Most frequent serious events
EventNiacin Extended-release Plus SimvastatinAtorvastatin
Chest painGeneral disorders1/1141/79
Coronary artery diseaseCardiac disorders1/1140/79
Most frequent other events
Showing 10 of 20
Most frequent other events
EventNiacin Extended-release Plus SimvastatinAtorvastatin
FlushingVascular disorders77/1148/79
VomitingGastrointestinal disorders11/1140/79
DiarrheaGastrointestinal disorders9/1142/79
NauseaGastrointestinal disorders9/1140/79
HeadacheNervous system disorders9/1142/79
PruritusSkin and subcutaneous tissue disorders7/1140/79
MyalgiaMusculoskeletal and connective tissue disorders4/1144/79
ConstipationGastrointestinal disorders5/1140/79
Tooth infectionInfections and infestations3/1140/79
Pain in extremityMusculoskeletal and connective tissue disorders3/1141/79

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Niacin Extended-release Plus SimvastatinAtorvastatinTotal
<=18 years000
Between 18 and 65 years9373166
>=65 years21627
Age Continuous
Age Continuous(years)Niacin Extended-release Plus SimvastatinAtorvastatinTotal
Mean55.1 ± 12.0651.5 ± 11.1253.6 ± 11.80
Sex: Female, Male
Sex: Female, Male(Participants)Niacin Extended-release Plus SimvastatinAtorvastatinTotal
Female7138109
Male434184
Region of Enrollment
Region of Enrollment(participants)Niacin Extended-release Plus SimvastatinAtorvastatinTotal
United States11479193
08

Study locations

46 sites
  • Anaheim, California 92801, United States
  • Huntington Park, California 90255, United States
  • Long Beach, California 90822, United States
  • Sacramento, California 95825, United States
  • Walnut Creek, California 94598, United States
  • Brooksville, Florida 34613, United States
  • Daytona Beach, Florida 32117, United States
  • Gainesville, Florida 32605, United States
  • Largo, Florida 33770, United States
  • Merritt Island, Florida 32953, United States
  • Miami, Florida 33126, United States
  • Pembroke Pines, Florida 33026, United States
  • Calhoun, Georgia 30701, United States
  • Decatur, Georgia 30034, United States
  • Dunwoody, Georgia 30338, United States
  • Boise, Idaho 83704, United States
  • Chicago, Illinois 60607, United States
  • Arkansas City, Kansas 67005, United States
  • Newton, Kansas 67114, United States
  • Shawnee Mission, Kansas 66216, United States
  • Topeka, Kansas 55508, United States
  • Wichita, Kansas 67203, United States
  • Auburn, Maine 04210, United States
  • Baltimore, Maryland 21204, United States
  • Missoula, Montana 59808, United States
  • Charlotte, North Carolina 28204, United States
  • High Point, North Carolina 27262, United States
  • Canfield, Ohio 44406, United States
  • Cincinnati, Ohio 45242, United States
  • Dayton, Ohio 45458, United States
  • Protland, Oregon 97239, United States
  • Chicora, Pennsylvania 16025, United States
  • Duncansville, Pennsylvania 16635, United States
  • Harleysville, Pennsylvania 19438, United States
  • Pittsburgh, Pennsylvania 15206, United States
  • Austin, Texas 78752, United States
  • Carrollton, Texas 75006, United States
  • Dallas, Texas 75251, United States
  • Houston, Texas 77074, United States
  • San Antonio, Texas 78224, United States
  • Magna, Utah 84044, United States
  • Salt Lake City, Utah 84107, United States
  • Richmond, Virginia 23249, United States
  • Gig Harbor, Washington 98335, United States
  • Menomonee Falls, Wisconsin 53051, United States
  • Milwaukee, Wisconsin 53209, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007 and a primary completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2009, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2007
First posted
Apr 24, 2007
Start
Apr 2007
Primary completionActual
Feb 2008
Results first posted
May 13, 2009
Last update
Jun 13, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00465088
Lead sponsor
Abbott
First posted
Apr 24, 2007
Start date
Apr 2007
Primary completion
Feb 2008
Results posted
May 13, 2009
Last update
Jun 13, 2011

Study contacts

Roopal Thakkar, MD
study director · Abbott
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Niacin · Simvastatin · Atorvastatin

Start the discussion